Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

Annual Report, Notice of Annual General Meeting and Board Change

Winsford, UK – 30 April 2021: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that the Annual Report and Accounts for the year ended 31 December 2020 and Notice of Annual General Meeting were posted to shareholders today and are available on the Investor Relations section of the Group’s website.

Annual General Meeting

The Board continues closely to monitor the coronavirus pandemic and our priority at this time remains the health, safety and well-being of all of our stakeholders. As part of its monitoring, the Board has noted, in particular, the gradual easing of public health restrictions across England in line with the government’s “COVID-19 Response – Spring 2021” roadmap published in February 2021.

Based on that roadmap and associated guidance, it is currently anticipated that attendance in person at the meeting will not be unlawful. It is therefore intended that the Directors will be present in person at the AGM, observing relevant social distancing guidelines in place on the date of the meeting. However, given ongoing public health considerations, you are strongly encouraged not to attend the meeting in person.

The Annual General Meeting notice and proxy forms were posted to shareholders today and are available on the Group’s website at www.admedsol.com/investor-relations. The AGM will be convened with the minimum necessary quorum of two shareholders. The outcome of the resolutions will as usual be determined by shareholder vote based on the proxy votes received.

Shareholders are therefore strongly encouraged to vote by proxy on the resolutions contained in the AGM Notice and to appoint the “Chairman of the Meeting” as their proxy, providing instructions on how the Chair should vote on the proposed resolutions. This will ensure that your votes will be counted if you (or any other proxy who you might otherwise appoint) choose not to attend the AGM in person.

To ensure votes are counted at the AGM, completed proxy forms should be returned to: Link Group, PXS, 10th Floor, Central Square, 20 Wellington Street, Leeds, LS1 4DL and must be received by 11.00 am on 4 June 2021 in order to be valid. This is particularly important given that COVID-19 continues to cause delays to the collection and delivery of postal services. Any shareholder who nonetheless wishes to attend the AGM in person is asked to register their intention to do so as soon as practicable.

The results of the AGM will be announced to the London Stock Exchange and placed on the Group’s website, in the usual way, as soon as practicable after the conclusion of the AGM.

Non-Executive Board Succession Planning and Change

In accordance with the 2018 UK Corporate Governance Code, and as outlined at the 2020 AGM, the Group is in the process of recruiting further Non-Executive Directors as part of the plan for Board refreshment.

Peter Steinmann retired at the 2020 AGM and Steve Bellamy is due to retire from the Board at the upcoming 2021 AGM. Grahame Cook, who joined the Board in February, will become Chairman of the Audit Committee. The Board would like to thank Steve for his significant contribution to the success of AMS over the last fourteen years.

The Board refreshment process will continue over the next two years. AMS will ensure that new Non-Executive Directors are appointed in a timely manner to allow for a smooth and effective handover.

– End –

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand^®, RESORBA^®, LiquiBandFix8^® and Seal-G^®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal^® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for woundcare and bio-diagnostics products based in the UK.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com.